Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00111904 · ClinicalTrials.gov registry record · Phase 2
Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer
A Phase 2 study of Pancreatic Cancer, sponsored by Theradex.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
- 5
- Study locations
NCT00111904 is a Phase 2 study of Pancreatic Cancer that has completed, run by Theradex. The registered enrollment target is 43 participants, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower). The trial reports 5 study locations across 5 states.
The verdict
NCT00111904, a Phase 2 study of Pancreatic Cancer, has completed, sponsored by Theradex.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
- 5
- Study locations
Study Summary
RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel works in treating patients with unresectable locally advanced or metastatic pancreatic cancer.
Conditions Studied
Interventions
- DRUG paclitaxel-loaded polymeric micelle
Study Locations (5)
Florida
- Florida Cancer Specialists - Bonita Springs - Bonita Springs
Illinois
- Midwest Cancer Research Group, Incorporated - Skokie
Louisiana
- Louisiana Oncology Associates - Lafayette - Lafayette
New York
- St. Vincent's Comprehensive Cancer Center - Manhattan - New York
Texas
- Southwest Regional Cancer Center - Central - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2005-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00111904
The ClinicalTrials.gov registry entry for NCT00111904 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 393-participant average among 278 other Pancreatic Cancer trials with a reported enrollment target (89% lower). The listed sponsor is Theradex, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Pancreatic Cancer appearing as the primary indexed condition, and to 1 intervention - of which paclitaxel-loaded polymeric micelle is the first listed.
NCT00111904 reports 5 study locations spanning 5 distinct geographic areas - top geographies include Florida, Illinois, Louisiana.
Frequently Asked Questions
What is clinical trial NCT00111904 about?
NCT00111904 is a clinical study titled "Paclitaxel in Treating Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer". RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. PURPOSE: This phase II trial is studying how well paclitaxel works in treating patients with unresectable locally advan...
What is the current status of trial NCT00111904?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2005-05.
What conditions does trial NCT00111904 study?
This clinical trial studies the following conditions: Pancreatic Cancer.
What interventions are being tested in trial NCT00111904?
The interventions under investigation include: paclitaxel-loaded polymeric micelle (DRUG).
Who is sponsoring clinical trial NCT00111904?
This trial is sponsored by Theradex, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00111904 being conducted?
This trial has 5 study locations across Florida, Illinois, Louisiana, New York, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatic Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
Pancreatic Cancer Adaptive Neoadjuvant Chemotherapy Trial
RECRUITING · Phase 2
-
Modulation of the Gut Microbiome With Pembrolizumab Following Chemotherapy in Resectable Pancreatic Cancer
RECRUITING · Phase 2
-
Study of Amplitude-Modulated Radiofrequency Electromagnetic Fields in Metastatic Pancreatic Cancer
RECRUITING · Phase 2
-
PurIST Classification-Guided Adaptive Neoadjuvant Chemotherapy by RNA Expression Profiling of EUS Aspiration Samples
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.